Eli Lilly Says Lebrikizumab Monthly Maintenance Dosing At Two Years Demonstrated Efficacy For Patients With Eczema

Eli Lilly And Company LLY said patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance.

Eli Lilly said patients saw itch relief and reduced disease severity with monthly maintenance dosing, as demonstrated in the ADjoin long-term extension study.

Lebrikizumab is an interleukin-13 (IL-13) inhibitor that specifically blocks IL-13 signaling. 

The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.

ADjoin is the two-year extension of the lebrikizumab monotherapy trials ADvocate 1 and ADvocate 2 and ADhere, the combination trial with topical corticosteroids.

In ADjoin, lebrikizumab provided durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing.

"Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials," Lotus Mallbris, senior vice president of global immunology development and medical affairs at Lilly.

"These data also further our understanding of the long-lasting benefits of lebrikizumab as a potential first-line biologic treatment for patients."

Results from ADjoin will be presented at the 43rd Annual Fall Clinical Dermatology Conference from October 19-22 in Las Vegas.

Price Action: LLY shares are trading lower by 1.47% at $582.10 on the last check Friday.

Photo Via Company